VIP vasoactive intestinal peptide
The action of vasoactive intestinal peptide antagonists on peptidergic modulation of the squid Schwann cell
... The effects of two specific antagonists of vasoactive intestinal peptide VIP receptors were investigated on the VIP-induced hyperpolarization of the membrane potential of the Schwann cel[r] ...
12
Treatment of Acute Respiratory Distress Syndrome with Vasoactive Intestinal Peptide
... results, VIP was proposed as a potential treatment for ARDS in 1996, but was not synthesized in sufficient quantity for study under FDA Investigational New Drug (IND) permission until ...intravenous VIP ...
11
Inhibition of murine embryonic growth by human immunodeficiency virus envelope protein and its prevention by vasoactive intestinal peptide and activity dependent neurotrophic factor
... This study reports that the HIV envelope protein has growth-inhibiting actions that can be prevented by VIP or ADNF. Prenatal growth inhibition (9–13) and the similar ini- tial growth retardation (14) seen among ...
6
Vasoactive Intestinal Peptide Stimulation of Adenylate Cyclase and Active Electrolyte Secretion in Intestinal Mucosa
... mucosa, VIP (20 µg/ml) caused a prompt fivefold increase in cyclic AMP level, whereas nine other hormones, which have been postulated to cause intestinal secretion, failed to exert such an ...a VIP ...
10
PACAP and its role in primary headaches
... and vasoactive intestinal peptide (VIP) are members of the VIP/secretin/growth hormone-releasing hormone/glucagon neuropeptide superfamily, widely expressed in vertebrate tissues ...
7
Importance of the Vasoactive Intestinal Peptide Receptor in the Stimulation of Cyclic Adenosine 3′,5′ Monophosphate in Gallbladder Epithelial Cells of Man: COMPARISON WITH THE GUINEA PIG
... native VIP. VIP strongly stimulated adenosine 3¢:5¢ monophosphate (cyclic AMP) production in human gallbladder epithelial ...nM VIP raised cyclic AMP levels 44 and 100 times above the basal level, ...
12
Maternal vasoactive intestinal peptide and the regulation of embryonic growth in the rodent
... E9.5, VIP dramatically acceler- ated embryonic growth ...with VIP re- sulted in a doubling of the DNA content and stimulated mitosis as measured by concentration-dependent increases in the number of cells ...
8
Vasoactive Intestinal Peptide (VIP) and VIP Receptors Elucidation of Structure and Function for Therapeutic Applications
... The distribution of VPAC1 and VPAC2 has been ex- tensively analyzed. VPAC1 is expressed in the liver, lungs, kidneys, prostate gland, mammary glands, spleen, lymphocytes, mucosa of the stomach and small intestine, and ...
9
Vasoactive intestinal peptide (VIP) differentially affects inflammatory immune responses in human monocytes infected with viable Salmonella or stimulated with LPS
... increased apoptosis of blood monocytes and increased survival of sepsis patients has been.. previously reported 24 and elevated monocyte numbers has also been reported to correlate.[r] ...
28
Ventilatory and cardiovascular actions of centrally and peripherally administered trout pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) in the unanaesthetized trout
... and VIP, injected ...and VIP cannot be determined from the present study. Since PACAP and VIP were injected in close proximity to the NPO they might mimic the action of the endogenous peptides that ...
9
Vasoactive intestinal peptide in human nasal mucosa
... Vasoactive intestinal peptide (VIP), which is present with acetylcholine in parasympathetic nerve fibers, may have important regulatory functions in mucous ...for VIP in human nasal ...
8
Therapeutic effect of vasoactive intestinal peptide on form-deprived amblyopic kittens
... digested with protease K (20 μg/ml) at 37 °C for 25 min. Then, 3% methanol-hydrogen peroxide was added, and the slide was placed in phosphate buffer saline (PH7.4) to block endogenous peroxidase. After pre-hybridization, ...
9
Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review
... of VIP binding sites were found in the pulmonary vascular smooth muscle layer and in airway smooth muscle of large, but not smaller ...airways. VIP binding sites are also present in sub-mucosal glands, air- ...
8
Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension
... the peptide in pul- monary arteries prepared from resected lungs of con- trol patients revealed moderate expression of VIP (Fig- ure ...of VIP immunoreactive nerve fibers in the control patients was ...
9
PACAP and its receptors in cranial arteries and mast cells
... activating peptide (PACAP), which exists in the body as 38- and 27- amino acid pep- tides [4, ...member vasoactive intestinal peptide (VIP) ...
11
Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro
... of VIP. Bipha- sic responses to peptides of the VIP family have been reported previously in other ...example, VIP at 50 pM stimulated proliferation of cultured retinal-pigmented epithelium cells, ...
12
Actin reorganization is involved in vasoactive intestinal peptide induced human mast cells priming to fraktalkine-induced chemotaxis
... between vasoactive intestinal peptide (VIP) and fraktalkine (FKN) in recruiting human mast cells to the asthmatic airway that provided a classical example of priming effect on mast cells ...
6
Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain
... intact VIP to the brain in rats, by using an intranasal route of administration (Dufes et ...pathway, VIP not only circumvents the BBB, but the polypeptide also avoids the hepatic first-pass effect and/or ...
9
Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats
... The intranasal administration procedure was based on the in situ nasal multipass perfusion method of Hirai et al. (1981). Overnight fasted male Sprague– Dawley rats (250–300 g) were anesthetized by in- traperitoneal ...
11
Localization and function of VIP and PACAP in the heart
... Vasoactive intestinal peptide (VIP) is a linear 28-amino-acid peptide with molecular weight of 3,326 Da that is generated by enzymatic cleavage from its precursor molecule, ...of ...
6